Ukraine faces challenges in financing the healthcare sector in 2024-2025. According to the analysis of the CF ‘Patients of Ukraine’, the state budget for 2025 provides UAH 11.8 billion for the procurement of medicines and medical devices, which is only 59.6% of the required amount. An additional UAH 8 billion is needed to fully meet the needs of patients.
The situation is also difficult in the procurement of expensive innovative medicines for the treatment of serious diseases. The budget allocates UAH 264.8 million, which covers only 13.2% of the needs. More than UAH 1.7 billion is needed to procure such medicines as Kitruda, Alekenza, and Venclisto.
Read also: Ukraine received $100 million in concessional funding from the Republic of Korea to support social services
The problem is particularly acute among patients with rare diseases. For example, adults with haemophilia are only 25% covered by medicines, while children are 35% covered. In many regions of Ukraine, medicines for the treatment of pulmonary arterial hypertension have been unavailable since November.
The supply issues also affect oncology patients: some regions have not received the planned deliveries of drugs such as Exemestane and Erlotinib. In addition, the issues of providing medicines for patients with multiple sclerosis, epilepsy, Crohn’s disease and other rare diseases remain unresolved.
Experts emphasise the need to review the financing of the medical sector and develop a strategy to increase the availability of medicines. Solving these problems requires both an increase in public funding and the search for alternative sources of support, including charitable and international funds.
Read also: “National cashback”: One-fifth of Ukrainians who received funds for September already spent them
